AIM ImmunoTech Inc (AIM) - Financial and Strategic SWOT Analysis Review
- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
HighlightsAIM ImmunoTech Inc (AIM ImmunoTech), formerly Hemispherx Biopharma Inc, is an immuno- pharma company. The company focuses on the research and development of therapeutics for the treatment of multiple types of cancers, viruses and immune-deficiency disorders. Its flagship products include Ampligen (rintatolimod) sterile solution which is indicated for the treatment of patients with chronic fatigue syndrome; and Alferon N Injection used for the treatment of refractory or recurrent external condylomata acuminate. The company’s pipeline products are intended to treat various types of cancers, including ovarian, breast, colorectal, melanoma, renal cell carcinoma, pancreatic, bladder cancers, MERS and influenza virus. The company operates a production facility in New Brunswick, New Jersey. AIM ImmunoTech is headquartered in Ocala, Florida, the US.
AIM ImmunoTech Inc Key Recent Developments
Aug 15,2023: AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update
Aug 09,2023: AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast
Mar 30,2023: AIM ImmunoTech bolsters Board of Directors with appointment of pharmaceutical industry veteran Nancy K. Bryan, with deep commercial, marketing, business development and corporate finance expertise
Mar 27,2023: AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast
Key benefits of buying this profile include:You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company